Clinical trials: Nervousness
Multiple Sclerosis, Relapsing-Remitting
RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial
To observe the safety and effectivity of a Recombinant Human B Lymphocyte Stimulator Receptor : Immunoglobulin G( IgG ) Fc Fusion Protein for injection (RC18) in patients with relapsing remitting multiple sclerosis, analyze the…
- Trial name
- NCT04625153
- Testing
- RC18 160mg, RC18 240mg
- Where
- China
- Volunteers
- 8 people
- Sponsor
- RemeGen Co., Ltd.
Traumatic Brain Injury With Persistent Cognitive Deficits
An Extension Study Evaluating the Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury (TBI) With Persistent Cognitive Deficits
Patients who completed the 12-week double blind protocol may enter this 26-week, open-label extension. This extension will give patients who complete the study an opportunity to receive treatment with open-label rivastigmine 3-12…
- Trial name
- NCT00219245
- Testing
- Rivastigmine
- Volunteers
- 157 people
- Sponsor
- Novartis
Relapsing-Remitting Multiple Sclerosis
Safety and Tolerability of Glatiramer Acetate
This is an open-label, randomized, multi-center, parallel-arm study to assess the safety and tolerability of a daily dose of Glatiramer Acetate (GA) 40 mg/mL three times a week (TIW) administered subcutaneously (SC) as compared…
- Trial name
- GLACIER (NCT01874145)
- Testing
- GA 20 mg/mL, GA 40 mg/mL
- Where
- 35 sites in United States
- Volunteers
- 209 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Low Muscle Strength, Malnutrition
Efficacy of Oral Nutritional Supplement in Community-Dwelling Adults Following Acute Care
The study aims to determine the effects of Oral Nutritional Supplement (ONS) added to usual care on body weight compared with usual care alone in community-dwelling adults aged 55 years and older who are at risk of malnutrition…
- Trial name
- NCT07753239
- Testing
- ONS, Standard of Care (SOC)
- Where
- 7 sites in Thailand
- Volunteers
- 304 people
- Sponsor
- Abbott Nutrition
Alzheimer Disease
Long-Term Safety Extension With SR57667B in Patients With Alzheimer's Disease
The primary objective is to assess the long term safety/tolerability of 4 mg/day of SR57667B in comparison to placebo in patients with mild-to-moderate Alzheimer's Disease (AD).
- Trial name
- NCT00285077
- Testing
- SR57667B
- Where
- 7 sites in Canada, Denmark and 5 more
- Volunteers
- 390 people
- Sponsor
- Sanofi
Normal Pressure Hydrocephalus
Normal Pressure Hydrocephalus (NPH) Registry
The overall aim of the registry is to develop a longitudinal, observational database that is focused on adult patients with Normal Pressure Hydrocephalus (NPH) that can be used as a source of clinical information for individual…
- Trial name
- NCT00233701
- Where
- 28 sites in United States
- Volunteers
- 343 people
- Sponsor
- Codman & Shurtleff
Cisplatin-Induced Hearing Loss in Children Who Had Standard-risk Hepatoblastoma
A Compassionate Use Program to Provide Access to Sodium Thiosulfate
This is a CUP which is designed to provide treatment access of STS to pediatric patients for the protection from Cisplatin-Induced Hearing Loss in children who had standard-risk hepatoblastoma.
- Trial name
- NCT04132882
- Testing
- Sodium Thiosulfate (STS)
- Where
- Turkey (Türkiye)
- Sponsor
- TRPHARM
Ischemic Stroke
A Study of Survival and Outcome After Stroke
The objective of this study is to determine the natural history of acute ischemic stroke from large vessel thromboembolism in the brain.
- Trial name
- SOS (NCT01193569)
- Where
- United Kingdom
- Volunteers
- 142 people
- Sponsor
- Penumbra Inc.
Obstructive Sleep Apnea
DeVilbiss AutoAdjust With SmartFlex Comparative Study
There will be equivalent therapeutic effectiveness between SmartFlex and standard modes when using the DeVilbiss AutoAdjust device.
- Trial name
- NCT01203956
- Testing
- SmartFlex, Standard
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- DeVilbiss Healthcare LLC
Alzheimer's Disease
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
This is a multi-center, randomized, double-blind placebo-controlled safety study conducted in 2 study cohorts. In Cohort 1, subjects with Alzheimer's disease (n=250) will receive Dimebon 20 mg or placebo TID for 26 weeks.
- Trial name
- NCT00838110
- Testing
- Dimebon
- Where
- 118 sites in United States, Canada and 1 more
- Volunteers
- 742 people
- Sponsor
- Pfizer
Alzheimer's Disease, Vascular Dementia
BAC in Patient With Alzheimer's Disease or Vascular Dementia
The primary objective of this study is to evaluate the efficacy of BAC patients with Alzheimer's disease or vascular dementia.The secondary objective of this study is to evaluate the safety of BAC patients with Alzheimer's…
- Trial name
- NCT02467413
- Testing
- BAC, BAC Matched Vehicle
- Where
- Taiwan
- Sponsor
- Botanicure Co., Ltd.
Fibromyalgia
Investigation of AVACEN Thermal Exchange System for Fibromyalgia Pain
Hypothesis: Daily use of the AVACEN Thermal Exchange System for 4 weeks will show improved Fibromyalgia pain and functioning markers, as assessed by biomarkers and clinical and psychological assessment.
- Trial name
- AVACEN: TES (NCT01619579)
- Testing
- AVACEN Thermal Exchange System
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Avacen, Inc.
Neuralgia
Safety and Efficacy of AGN201781 in Neuropathic Pain
This study will explore the safety and efficacy of AGN201781 in patients with postherpetic neuralgia or post-traumatic peripheral neuralgia
- Trial name
- NCT00533351
- Testing
- AGN201781
- Where
- 2 sites in Australia, Germany
- Volunteers
- 9 people
- Sponsor
- Allergan
Refractory Partial Seizures
Evaluating Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
The purpose of this study is to evaluate the efficacy, safety and tolerability of perampanel when given as an adjunctive therapy in subjects with refractory partial seizures.
- Trial name
- NCT00700310
- Testing
- perampanel
- Where
- 137 sites in Australia, Bulgaria and 21 more
- Volunteers
- 712 people
- Sponsor
- Eisai Inc.
Diabetic Macular Edema, Diabetic Retinopathy
Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)
This is a prospective, observational study designed to evaluate the long-term safety and tolerability of ADVM-022 in participants with diabetic macular edema (DME).
- Trial name
- NCT05607810
- Testing
- ADVM-022
- Where
- 7 sites in United States, Puerto Rico
- Volunteers
- 22 people
- Sponsor
- Adverum Biotechnologies, Inc.
Relapsing Remitting Multiple Sclerosis
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12 month study where 852 patients with relapsing remitting MS will be randomized 1:1 to fingolimod or approved disease modifying therapy.
- Trial name
- PREFERMS (NCT01623596)
- Testing
- Fingolimod, Disease Modifying therapy
- Where
- 123 sites in United States, Puerto Rico
- Volunteers
- 881 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus, Systemic Sclerosis
Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases
This is an open-label, investigator-initiated clinical trial (IIT) aimed at evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-04 in patients with active SLE, SSc, AAV, IIM, and pSS
- Conditions
- Systemic Lupus Erythematosus, Systemic Sclerosis, ANCA Associated Vasculitis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT06549296
- Testing
- RD06-04 CART Cell Injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Nanjing Bioheng Biotech Co., Ltd.
Alzheimer Disease
Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease
This is a phase 2, open-label, multiple-center, non-randomized single dose study to assess the safety and efficacy of [18F]NAV4694 PET imaging in detecting beta-amyloid plaque in the brain in subjects with probable AD compared…
- Trial name
- NCT01680588
- Testing
- [18F]NAV4694
- Where
- 7 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Navidea Biopharmaceuticals
Amyotrophic Lateral Sclerosis, Fasciculation
Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS
The FLX-787-107 study will determine how well FLX-787-ODT works to reduce fasciculations in patients with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT03334786
- Testing
- FLX-787-ODT
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Flex Pharma, Inc.
Spinocerebellar Degeneration
A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
The purpose of this study is to evaluate the long-term safety, efficacy, and pharmacokinetics of KPS-0373 in SCD patients
- Trial name
- NCT01970124
- Testing
- KPS-0373, High dose, KPS-0373, Low dose
- Where
- Japan
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.